Eccdna associated with malignant transformation of hepatocellular carcinoma and obtaining method and application thereof

By extracting and analyzing eccDNA from plasma and tissue samples, the lack of early molecular markers for hepatocellular carcinoma has been addressed, enabling stable and non-invasive monitoring and diagnosis of malignant transformation of hepatocellular carcinoma, and providing a new method for risk assessment and prognostic analysis of HBV-related liver cancer.

CN122344575APending Publication Date: 2026-07-07SHENZHEN PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610546695.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-23
Publication Date
2026-07-07

AI Technical Summary

Technical Problem

There is a lack of stable, non-invasive, dynamically monitorable molecular markers for early hepatocellular carcinoma with mechanistic explanatory capabilities in the current technology.

Method used

eccDNA associated with malignant transformation of hepatocellular carcinoma is obtained through gene screening or artificial synthesis. The specific steps include extracting cell-free DNA from plasma and tissue samples, rolling circle amplification and purification of eccDNA, performing circle-seq and RNA-seq sequencing analysis, and screening out eccDNA with differential abundance and consistent expression as biomarkers.

Benefits of technology

eccDNA can be stably present in plasma and serve as an early molecular marker for the malignant transformation of hepatocellular carcinoma, providing a new technological approach for risk assessment, auxiliary diagnosis, and prognostic analysis of HBV-related liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122344575A_ABST
    Figure CN122344575A_ABST
Patent Text Reader

Abstract

The present application relates to a kind of eccDNA related to malignant transformation of hepatocellular carcinoma and its acquisition method and application, the nucleotide sequence of eccDNA is as shown in SEQ ID NO:1;The acquisition method and application of the eccDNA are also disclosed.The eccDNA obtained by the present application can exist stably in plasma and other body fluids, can be used for non-invasive or minimally invasive detection, can be used as early molecular marker of malignant transformation of hepatocellular carcinoma, and provides a new early warning idea of malignant transformation of hepatocellular carcinoma for the development of HBV-related liver cancer.
Need to check novelty before this filing date? Find Prior Art